Talk about 5G is everywhere right now, from the trade war with China to the ban on Huawei. Here's what 5G is and why it matters.Technologyread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
A slew of retail earnings the past two weeks makes it clear that while Americans continue to shop, they aren't ringing registers at department stores.Retailread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Stocks that would benefit from a federal infrastructure spending program fell after President Trump ended a meeting on infrastructure spending with Democratic leaders.Market Insiderread more
Despite the president's claim that "you can't investigate and legislate simultaneously," certain must-pass pieces of legislation, including a debt ceiling hike, will...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
Amazon shareholders demanded the company to take action on a number of different issues during its annual shareholder meeting on Wednesday.Technologyread more
Moody's said it's downgrading the outlook for Equifax from stable to negative, citing ongoing fallout from the company's 2018 data breach.Technologyread more
Controversial lawyer Michael Avenatti was indicted on charges of trying to extort athletic shoe giant Nike out of tens of millions of dollars by threatening to go public with...Politicsread more
Ireland-based Jazz Pharmaceuticals will buy U.S.-based Celator Pharmaceuticals in a cash deal valued at about $1.5 billion, to gain access to an investigational product in development for treating acute myeloid leukemia.
Celator shares soared 71 percent and were up 1609 percent year to date. Jazz's stock was slightly lower.
Jazz Pharmaceuticals will pay $30.25 per share in cash for Celator, a 72.6 percent premium to Celator's closing price on Friday.
In March, Ewing, New Jersey-based Celator said its Vyxeos treatment helped older high-risk patients with a deadly form of leukemia live longer than those who received the standard of care regimen in a late stage clinical trial.
In May, the company said the U.S. Food and Drug Administration had granted breakthrough therapy designation to Vyxeos.
The deal is expected to add to Jazz Pharma's non-GAAP adjusted earnings beginning in 2018, the companies said in a statement on Tuesday.
"As Celator is currently preparing a regulatory submission in the U.S. for Vyxeos, this acquisition would add a new orphan product with the potential for short- and long-term revenue generation and expansion of our international commercial platform," Jazz Pharmaceuticals Chief Executive Bruce Cozadd said in a statement.
Jazz Pharma will fund the deal, structured as a tender offer, with a combination of cash on hand and borrowings under its credit facility.
RBC Capital Markets was the financial advisor and Cooley was the legal counsel for Jazz Pharmaceuticals.